Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has launched famciclovir tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir tablets, a treatment for herpes.  

Famciclovir tablets had US sales of approximately $196 million for the 12 months ending December 31, 2010, according to IMS Health.

Currently, Mylan has 165 ANDAs pending US FDA approval representing $98.5 billion in annual sales, according to IMS Health. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $25.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc.ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies.